BlackRock’s Akebia Therapeutics AKBA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $26M | Sell |
18,693,296
-625,156
| -3% | -$859K | ﹤0.01% | 2917 |
|
|
2025
Q4 | $31.1M | Buy |
19,318,452
+521,394
| +3% | +$1.09M | ﹤0.01% | 2813 |
|
|
2025
Q3 | $51.3M | Buy |
18,797,058
+423,097
| +2% | +$1.41M | ﹤0.01% | 2477 |
|
|
2025
Q2 | $66.9M | Buy |
18,373,961
+3,041,798
| +20% | +$8.36M | ﹤0.01% | 2285 |
|
|
2025
Q1 | $29.4M | Buy |
15,332,163
+234,538
| +2% | +$479K | ﹤0.01% | 2711 |
|
|
2024
Q4 | $28.7M | Sell |
15,097,625
-99,582
| -0.7% | -$173K | ﹤0.01% | 2817 |
|
|
2024
Q3 | $20.1M | Buy |
15,197,207
+3,558,723
| +31% | +$4.75M | ﹤0.01% | 3044 |
|
|
2024
Q2 | $11.9M | Buy |
11,638,484
+9,099,259
| +358% | +$11.2M | ﹤0.01% | 3284 |
|
|
2024
Q1 | $4.65M | Sell |
2,539,225
-583,599
| -19% | -$933K | ﹤0.01% | 3700 |
|
|
2023
Q4 | $3.87M | Buy |
3,122,824
+669,051
| +27% | +$682K | ﹤0.01% | 3793 |
|
|
2023
Q3 | $2.8M | Sell |
2,453,773
-283,083
| -10% | -$364K | ﹤0.01% | 3884 |
|
|
2023
Q2 | $2.5M | Buy |
2,736,856
+33,333
| +1% | +$32.2K | ﹤0.01% | 3960 |
|
|
2023
Q1 | $1.52M | Sell |
2,703,523
-219,022
| -7% | -$167K | ﹤0.01% | 4178 |
|
|
2022
Q4 | $1.69M | Sell |
2,922,545
-1,364,411
| -32% | -$428K | ﹤0.01% | 4203 |
|
|
2022
Q3 | $1.36M | Sell |
4,286,956
-53,070
| -1% | -$20.8K | ﹤0.01% | 4370 |
|
|
2022
Q2 | $1.53M | Sell |
4,340,026
-9,621,514
| -69% | -$4.04M | ﹤0.01% | 4360 |
|
|
2022
Q1 | $10M | Sell |
13,961,540
-162,675
| -1% | -$348K | ﹤0.01% | 3578 |
|
|
2021
Q4 | $31.9M | Buy |
14,124,215
+71,728
| +0.5% | +$196K | ﹤0.01% | 2985 |
|
|
2021
Q3 | $40.5M | Buy |
14,052,487
+877,806
| +7% | +$2.51M | ﹤0.01% | 2801 |
|
|
2021
Q2 | $49.9M | Buy |
13,174,681
+805,695
| +7% | +$2.71M | ﹤0.01% | 2705 |
|
|
2021
Q1 | $41.9M | Buy |
12,368,986
+971,438
| +9% | +$3.5M | ﹤0.01% | 2736 |
|
|
2020
Q4 | $31.9M | Sell |
11,397,548
-346,614
| -3% | -$1.01M | ﹤0.01% | 2748 |
|
|
2020
Q3 | $29.5M | Buy |
11,744,162
+380,299
| +3% | +$3.34M | ﹤0.01% | 2636 |
|
|
2020
Q2 | $154M | Buy |
11,363,863
+1,229,244
| +12% | +$12.7M | 0.01% | 1544 |
|
|
2020
Q1 | $76.8M | Sell |
10,134,619
-126,528
| -1% | -$984K | ﹤0.01% | 1805 |
|
|
2019
Q4 | $64.9M | Sell |
10,261,147
-319,273
| -3% | -$1.52M | ﹤0.01% | 2201 |
|
|
2019
Q3 | $41.5M | Buy |
10,580,420
+352,730
| +3% | +$1.51M | ﹤0.01% | 2414 |
|
|
2019
Q2 | $49.5M | Buy |
10,227,690
+1,745,307
| +21% | +$9.93M | ﹤0.01% | 2324 |
|
|
2019
Q1 | $69.5M | Buy |
8,482,383
+185,880
| +2% | +$1.28M | ﹤0.01% | 2095 |
|
|
2018
Q4 | $45.9M | Buy |
8,296,503
+3,027,657
| +57% | +$23.7M | ﹤0.01% | 2292 |
|
|
2018
Q3 | $46.5M | Buy |
5,268,846
+253,811
| +5% | +$2.27M | ﹤0.01% | 2413 |
|
|
2018
Q2 | $50M | Buy |
5,015,035
+717,328
| +17% | +$7.18M | ﹤0.01% | 2353 |
|
|
2018
Q1 | $41M | Buy |
4,297,707
+392,201
| +10% | +$5.49M | ﹤0.01% | 2387 |
|
|
2017
Q4 | $58.1M | Buy |
3,905,506
+152,402
| +4% | +$2.53M | ﹤0.01% | 2192 |
|
|
2017
Q3 | $73.8M | Buy |
3,753,104
+1,008,497
| +37% | +$15.5M | ﹤0.01% | 2040 |
|
|
2017
Q2 | $39.4M | Buy |
2,744,607
+56,535
| +2% | +$717K | ﹤0.01% | 2399 |
|
|
2017
Q1 | $24.7M | Buy |
2,688,072
+2,680,345
| +34,688% | +$26.2M | ﹤0.01% | 2628 |
|
|
2016
Q4 | $80K | Buy |
7,727
+557
| +8% | +$4.8K | ﹤0.01% | 2686 |
|
|
2016
Q3 | $65K | Buy |
7,170
+488
| +7% | +$4.15K | ﹤0.01% | 2838 |
|
|
2016
Q2 | $50K | Buy |
6,682
+4,461
| +201% | +$38.9K | ﹤0.01% | 2930 |
|
|
2016
Q1 | $20K | Sell |
2,221
-3,288
| -60% | -$26.7K | ﹤0.01% | 2838 |
|
|
2015
Q4 | $71K | Buy |
5,509
+239
| +5% | +$2.44K | ﹤0.01% | 1887 |
|
|
2015
Q3 | $51K | Buy |
5,270
+5,000
| +1,852% | +$45.9K | ﹤0.01% | 1899 |
|
|
2015
Q2 | $3K | Hold |
270
| – | – | ﹤0.01% | 3184 |
|
|
2015
Q1 | $3K | Hold |
270
| – | – | ﹤0.01% | 3094 |
|
|
2014
Q4 | $3K | Hold |
270
| – | – | ﹤0.01% | 3125 |
|
|
2014
Q3 | $6K | Sell |
270
-11,428
| -98% | -$263K | ﹤0.01% | 2994 |
|
|
2014
Q2 | $326K | Buy |
+11,698
| New | +$282K | ﹤0.01% | 1398 |
|
Other funds holding AKBA
VCM
VPM
BlackRock's AKBA Position: Q1 2026 in Review
BlackRock reduced its Akebia Therapeutics (AKBA) stake by 3.2% in Q1 2026, selling an estimated $859K and leaving 18,693,296 shares worth $26M. The position accounts for ﹤0.01% of the portfolio, ranked #2917.
BlackRock first reported a position in AKBA in Q2 2014 and has held it in 48 quarters since. The position peaked at $154M in Q2 2020. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.
- BlackRock held 18,693,296 shares of Akebia Therapeutics worth $26M as of Q1 2026.
- BlackRock sold 625,156 Akebia Therapeutics shares in Q1 2026, an estimated $859K.
- Akebia Therapeutics made up ﹤0.01% of BlackRock's portfolio in Q1 2026, its #2917 holding.
- BlackRock first reported a position in Akebia Therapeutics in Q2 2014 and has held it in 48 quarters since.
- BlackRock's Akebia Therapeutics position peaked at $154M in Q2 2020.
- 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.
Based on BlackRock's 13F filing for Q1 2026, filed 13 May 2026.